The main aim of this study is to investigate the effectiveness of a new drug (ANAVEX 2-73) in treating early Alzheimer’s disease. Two clinical studies investigating use of ANAXVEX 2-73 in human subjects have been completed and have shown positive outcomes in cognition, such as memory, attention, speed of processing and reasoning and problem solving.
The current study extends on previous findings to further investigate the effect of this drug (including at varying dose levels) on cognitive and functional outcomes – the former being various aspects of thinking abilities and the latter being independence in completion of daily activities.
The purpose of this research study is to compare the effects of the study drug, PF-06687234, with a placebo while also being treated with infliximab to find out which is better for treating Ulcerative Colitis (UC).
The study drug, PF-06687234 has two proteins that are connected to each other. One protein seeks out and attaches to areas of inflammation (for example the colon in UC). The second protein works to “calm down” the immune system in inflamed areas such as the colon, in UC. A placebo looks like the study drug but does not contain any active drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.
PF-06687234 is an experimental drug which means that it is not an approved treatment for UC in Australia.
he purpose of the study is to evaluate the safety and effectiveness of the study drug tezepelumab alone, or in combination with a topical corticosteroid, in the treatment of moderate to severe atopic dermatitis. Atopic dermatitis is a chronic, inflammatory skin condition with symptoms including areas of dry, itching and reddened skin. This study will also assess the safety and effectiveness of different doses of tezepelumab.
Tezepelumab is an experimental treatment which means that it is not an approved treatment for moderate to severe atopic dermatitis in Australia. Medications, drugs and devices have to be approved for use by the Therapeutic Goods Administration in Australia.
Alopecia areata is an autoimmune disease characterised by loss if hair in single or multiple areas of the scalp, face or body. The scalp is most commonly affected.
The purpose of this study is to compare the effects of the PF-06651600 with a placebo to find out which is better for treating alopecia areata. Researchers will compare the results of taking the placebo to the results of taking PF-06651600 to see if there are any differences.
Psoriasis is a chronic inflammatory skin disorder, characterised primarily by scaly plaques, that affects up to 3% of the general population. Many patients with severe disease are still being managed with only topical treatments, and many patients consider their psoriasis treatment to be inadequate.
The purpose of this research project is to measure how safe and effective BMS-986165 (the investigational drug) is in treating participants with moderate-to-severe plaque psoriasis. Prior research studies have shown that BMS-986165 may help control the immune system that is responsible for the signs and symptoms of psoriasis by controlling the molecules in the body responsible for inflammation within the skin.
Palmoplantar pustulosis (PPP) is a skin condition that causes blister-like sores to show up on the palms of your hands and the soles of your feet. It can also cause cracked skin or reddened, scaly patches.
CSL324 is a new biological drug, a protein called an antibody. Antibodies are usually produced by special immune cells to fight infections (bacteria, viruses or other intruders into the body). The antibody CSL324 works by blocking the activity of a growth factor called “granulocyte-colony stimulating factor” which is responsible for stimulating the bone marrow to produce white blood cells and stem cells and release them into the bloodstream. Researchers believe this antibody may be able to help decrease inflammation in many inflammatory diseases such as PPP where white blood cells have been mobilised.
CSL324 is an experimental treatment. This means that it has not been approved for treating PPP by the Therapeutic Goods Administration in Australia.
Vitiligo is a chronic skin disorder characterised by a patchy loss of skin colour. This loss of skin colour could be focused in one area of the body for some patients (called “segmental vitiligo”) or could be dispersed over various areas of the body for other patients (called “non‑segmental vitiligo”). In human beings, melanin, a biological molecule, is responsible for skin colour and is called the skin pigment. Melanin is produced by certain types of cells in the body called melanocytes. In vitiligo, the skin loses these melanocytes due to complex reactions involving many different biological molecules.
PF‑06651600 and PF‑06700841 are study drugs and are being developed as possible treatments for patients with non‑segmental and active vitiligo.
The study drugs act by blocking the activity of some of the biological molecules responsible for the loss of melanocytes. This project will explore whether the study drugs are effective in controlling vitiligo and if they are safe for human-use.
The purpose of this study is to compare the safety and effectiveness of PRN1008 as a treatment for pemphigus vulgaris (PV) and pemphigus foliaceus (PF) when taken with a corticosteroid and compare this to the safety and effectiveness of corticosteroid alone.
PRN1008 is an investigational drug developed by the study sponsor, Principia for the treatment of autoimmune and inflammatory diseases, such as pemphigus. PRN1008 is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in B-cell development, a type of white blood cell that is involved in the immune system, and in the white blood cells’ role in diseases like PV or PF.